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Resumo 
 
A nível mundial, o cancro do colo do útero é o quarto cancro mais comum em mulheres, e 
o sétimo em geral, com cerca de 528 mil novos casos diagnosticados em 2012. Existe uma 
estimativa de 266 mil mortes por esta doença no mesmo ano, representado 7,5% de todas 
as mortes por cancro feminino.  
 
A infeção pelo vírus do papiloma humano (HPV) é considerada o principal fator de risco 
para o desenvolvimento desta neoplasia. No entanto, a carcinogénese cervical parece ser 
dependente de uma série de eventos genéticos e epigenéticos celulares incluindo, entre 
outros, polimorfismos em genes associados à reparação do DNA (Ácido 
Desoxirribonucleico). Atualmente existem alguns estudos que sugerem que os 
polimorfismos genéticos nos genes XRCC1 (X-repair cross complementing group 1) 
e ERCC2 (Excision repair cross-complementing group 2) parecem reduzir a capacidade de 
reparação do DNA e com potencial utilidade como marcadores moleculares para prever a 
resposta terapêutica e o prognóstico de doentes com cancro. O gene XRCC1 é um dos 
principais genes de reparação do DNA, estando envolvido na via de reparação por excisão 
de bases (BER), a qual desempenha um papel fundamental na reparação de pequenas 
lesões do DNA provocadas por danos de oxidação e alquilação. Por sua vez, o gene 
ERCC2 participa na via de reparação por excisão de nucleótidos (NER), através da 
reparação de ligações cruzadas de DNA e danos provocados por radiações ultravioletas e 
produtos químicos tóxicos. 
 
Este estudo foi desenvolvido com o objetivo de analisar o efeito dos polimorfismos 
genéticos XRCC1 rs1799782 e ERCC2 rs13181 na evolução clínica de doentes com 
cancro do colo do útero, nomeadamente na eficácia da resposta terapêutica, sobrevivência 
global e sobrevivência livre de doença. 
  
Neste trabalho, foi realizado um estudo do tipo coorte retrospetivo de base hospitalar 
incluindo 260 doentes caucasianas com diagnóstico histopatológico de cancro do colo do 
útero e estádios entre Ib2 e IVa. Todas as doentes foram admitidas e tratadas com 
quimioradioterapia concomitante à base de cisplatina, no Instituto Português de Oncologia 
do Porto. A análise dos polimorfismos genéticos foi realizada por discriminação alélica 
através da técnica PCR em tempo real e a análise estatística dos resultados foi efetuada 
com o auxílio do programa estatístico SPSS. 
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Os resultados obtidos demonstraram na nossa população que mulheres com cancro do 
colo do útero, gânglios linfáticos negativos e portadoras do genótipo CC do polimorfismo 
ERCC2 rs13181 apresentam uma sobrevivência global maior do que as doentes 
portadoras de um alelo A (p=0.044). Além disso, verificou-se que as doentes com doença 
avançada, nódulos linfáticos negativos e com o genótipo CC têm uma sobrevivência global 
maior do que mulheres portadoras de um alelo A (p=0.020). Adicionalmente, os resultados 
demonstraram que as doentes com doença avançada, idade superior a 39 anos e com o 
genótipo CC têm uma sobrevivência global maior do que mulheres portadoras de um alelo 
A (p=0.009) e apresentam um menor risco de recidiva (p=0.040). Utilizando a análise de 
regressão de Cox observamos que as doentes portadoras do em alelo A apresentam um 
risco de morte 9 vezes superior às mulheres com genótipo CC (p=0.030). 
Por fim, observou-se que as doentes com gânglios linfáticos positivos e portadoras de um 
alelo C para o polimorfismo ERCC2 rs13181 ou T para o polimorfismo XRCC1 rs1799782, 
têm uma sobrevivência global média menor do que as restantes mulheres (p=0.034). 
  
A realização deste estudo pode contribuir para a definição de um perfil farmacogenómico 
baseado no background genético das doentes com cancro do colo do útero, 
proporcionando-lhes um tratamento mais individualizado e, consequentemente, uma 
melhor evolução clínica e uma menor toxicidade. 
 
 
Palavras-chave: Cancro do colo do útero; XRCC1, ERCC2; Polimorfismos genéticos; 
Resposta ao tratamento; Sobrevivência global; Sobrevivência livre de doença. 
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Abstract 
 
Globally, cervical cancer is the fourth most common cancer in women, and the seventh 
overall, with about 528,000 new cases diagnosed in 2012. There is an estimated 266,000 
deaths from this disease in the same year, representing 7.5% of all deaths from female 
cancer. 
 
Human papillomavirus (HPV) infection is considered the main risk factor for the 
development of this neoplasm. However, cervical carcinogenesis appears to be dependent 
on a number of genetic and cellular epigenetic events including, but not limited to, 
polymorphisms in genes associated with DNA (Deoxyribonucleic Acid) repair. There are 
currently some studies that suggest that genetic polymorphisms in XRCC1 (X-repair cross 
complementing group 1) and ERCC2 (Excision repair cross-complementing group 2) genes 
appear to reduce DNA repair ability and potentially useful as molecular markers to predict 
the therapeutic response and the prognosis of cancer patients. The XRCC1 gene is one of 
the major DNA repair genes, being involved in the base excision repair (BER) pathway, 
which plays a key role in repairing small DNA damage caused by oxidation and alkylation 
damage. In turn, the ERCC2 gene participates in the nucleotide excision repair (NER) 
pathway, through the repair of DNA cross-links and damage caused by ultraviolet radiation 
and toxic chemicals. 
 
This study was developed with the objective of analyzing the effect of the XRCC1 rs1799782 
and ERCC2 rs13181 genetic polymorphisms on the clinical evolution of patients with 
cervical cancer, namely in the efficacy of the therapeutic response, overall survival and 
disease-free survival. 
 
In this study, hospital-based retrospective cohort study was performed including 260 
Caucasian patients with histopathological diagnosis of cervical cancer and stages between 
Ib2 and IVa. All patients were admitted to and treated with concomitant chemoradiotherapy 
based on cisplatin at the Portuguese Oncology Institute of Porto. Genetic polymorphisms 
analysis was performed by allelic discrimination using the real time PCR technique and the 
statistical analysis of the results was performed with the aid of the SPSS statistical program. 
Our results showed that women with cervical cancer, negative lymph nodes and patients 
with the CC genotype of the ERCC2 rs13181 polymorphism have an increased overall 
survival than patients with an A allele (p=0.044). Furthermore, patients with advanced 
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disease, lymph node negative and CC genotype have been found to have an increased 
overall survival than women carrier an A allele (p=0.020). Additionaly, among patients with 
advanced disease and older than 39 years, carriers of the CC genotype have an increased 
overall survival than women with an A allele (p=0.009) and show a lower risk of relapse 
(p=0.040). Using Cox regression analysis, we observed that patients with allele A present 
a 9-fold higher risk of death than women with CC genotype (p=0.030). Finally, patients with 
lymph nodes positive and carrying a C allele for the ERCC2 rs13181 or T polymorphism for 
the XRCC1 polymorphism rs1799782 were observed to have a decreased overall survival 
(p=0.034). 
The performance of this study may contribute to the definition of a pharmacogenomic profile 
based on the genetic background of patients with cervical cancer, providing them with a 
more individualized treatment and, consequently, a better clinical evolution and a lower 
toxicity. 
 
 
Key-words: Cervical cancer; XRCC1, ERCC2; Genetic polymorphisms; Treatment 
response; Overall Survival; Disease-free survival. 
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1. Cancer: General considerations 
 
Over the years, cancer has been a growing public health problem worldwide, with the 
incidence rates have increased in most countries since 1990 [1]. This disease is a leading 
cause of morbidity and mortality worldwide, with about 17 million new cases and more than 
8.7 million deaths in 2015, leaving behind only cardiovascular disease. Factors such as 
aging and population growth are contributing to the increase in the number of new cases, 
since between 2005 and 2015 it experienced a significant increase of 33%. However, 
although incidence rates have increased, many countries have suffered a decline in 
mortality from this disease [2]. 
In Portugal, 46,724 new cases of cancer were diagnosed in 2010, which corresponded to a 
cancer incidence rate of 441.9/100,000. The incidence rate was 507.7/100,000 in men 
(25,658 cases) and 381.7/100,000 in women (21066 cases). There was a 4.5% increase in 
the number of new cases compared to 2009 [3].  
Carcinogenesis is considered multi-stage tumor development process that results from the 
accumulation of various genetic and epigenetic changes in DNA (Deoxyribonucleic Acid), 
giving rise to the transformed phenotype and can be divided into three steps: tumor 
initiation, tumor promotion and tumor progression [4, 5]. The initiation of the tumor consists 
of the occurrence of changes that cause irreversible genetic damage. Tumor promotion 
comprises the selective clonal expansion of initiated cells, producing a larger population of 
cells that are at risk of further genetic changes and malignant conversion [4]. Over of time, 
many tumors become more aggressive and acquire greater malignant potential. This 
phenomenon is referred to as tumor progression [5]. 
As normal cells progressively evolve into a neoplastic state, they acquire a set of hallmarks 
that allow them to reach a state of malignancy, such as growth factor stimulation, 
insensitivity to inhibitory signals, activation of invasion and metastization, unlimited 
replicative potential, induction of angiogenesis and evasion of apoptosis (Figure 1). 
Underlying all these characteristics, genomic instability, which in turn generates genetic 
diversity, will speed up the process of acquiring these [6]. 
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Figure 1 - Hallmarks of cancer (6) 
 I. INTRODUCTION 
 
5 
2. Cervical Cancer 
2.1. Epidemiology 
 
Cervical cancer is the fourth most common cancer in women, and the seventh overall, with 
an estimated 528,000 new cases in 2012 and, with a small decrease, 526,000 in 2015 [2, 
7]. The discrepancy in cervical cancer incidence and mortality between developed and 
developing regions has become increasingly apparent, being that 85% of cases and cervical 
cancer deaths occur in countries with the worst living conditions [8]. There were an 
estimated 266,000 deaths from cervical cancer worldwide in 2012, accounting for 7.5% of 
all female cancer deaths, with almost 87% of these deaths occurring in developing countries 
(Figure 2) [7].  
 
 
 
Figure 2 - Estimated age-standardised rates (World) per 100,000 (7) 
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In Europe, in 2012, an annual incidence was estimated for every 100,000 women of about 
13.4 new cases and a mortality of 4.9 deaths. In turn, in Portugal, for the same year was 
predicted an incidence of 10.8 new cases and a mortality of 4.9 deaths per 100,000 women 
[9]. 
Vaccination against Human papillomavirus (HPV) appears to be a promising tool in the 
primary prevention of cervical cancer, reducing nearly 70% the probability to develop 
cervical cancer and consequently reducing incidence and mortality rate. Many countries 
have introduced HPV vaccination into their health-care systems, including Portugal [10]. 
 
2.2. Etiology and Risk Factors 
 
The most important risk factor for cervical cancer development is chronic persistent HPV 
infection [11, 12]. HPVs are a heterogeneous group of double-stranded DNA viruses and 
infection is a sexually transmitted disease [13]. However, HPV infection alone is an 
insufficient cause of cervical carcinogenesis. Most HPV infections spontaneously regress 
and only in a small percentage of cases the infection persists, low-grade intraepithelial 
lesions progress to highgrade lesions and, ultimately, develop into invasive cervical 
carcinoma [14]. 
Several global epidemiological studies indicate that there are 18 different types of high-risk 
HPVs, namely 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53,56, 58, 59, 66, 68, 73 and 82, which 
are associated with cervical cancer. HPV16 and HPV18 are the most carcinogenic types 
within this group, being responsible for approximately 50% and 20% of cervical cancer 
respectively [15]. 
Therefore, there are other factors that are associated with increased risk for development 
of the cervical cancer. As example, women who have many sexual partners or a partner 
with multiple sex partners are at increased risk for HPV infection and cervical cancer, as 
well as women who are positive for Human Immunodeficiency Virus (HIV). Long-term use 
of combined oral contraceptives may also be an important risk factor for this cancer type.  
Beside infection with others virus like chlamydia or herpes simplex virus 2 can be associated 
with chronic inflammation and microulcerative changes of the cervical epithelium that play 
an important role in initiation and progression of cancer. 
General lifestyle factors, including smoking, eating a diet low in fruits and vegetables and 
being overweight have been considered as co-factors for increase of the risk of cercical 
cancer. As well as, having a family history of cervical cancer and low socialeconomic 
conditions or limited access to health care [16].  
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2.3. Histopathology 
 
Although most infections resolve without consequence, persistent infections can lead to 
precancerous cervical lesions and, in a minority of women, invasive cancer. Figure 3 shows 
that the majority of all mild dysplasias regress spontaneously, however a proportion of the 
high-risk HPV infections will become persistent and, if left untreated, proceed to high-grade 
lesions and invasive cervical cancer [12]. The most common precancerous lesions are of 
squamous cell origin, called cervical intraepithelial neoplasia (CIN), and are graded by the 
proportion of abnormal epithelium (CIN grade 1, 2 and 3). The estimated time for CIN grade 
3 progression to cancer is on average 10 years, allowing many opportunities for these 
lesions to be found and treated [17]. 
 
 
 
The HPV genome encodes eight proteins, two of which, E6 and E7, account for most of the 
carcinogenic effects of high-risk types of HPV. These proteins have the ability to promote 
carcinogenesis by creating genomic instability and by inhibiting tumor suppressor genes. 
E6 and E7 directly promote genomic instability, which can result in large chromosomal 
rearrangements and copy number variations, by interfering with centromere duplication 
during mitosis. Both oncoproteins interfere with important cellular tumor suppressor 
pathways: E6 inhibits the p53 tumor suppressor by promoting its proteasomal degradation, 
while E7 disrupts the retinoblastoma (Rb) pathway resulting in uncontrolled activation of the 
cell cycle and induction of p16INK4A, a cyclin-dependent kinase inhibitor, through a 
disrupted feedback loop [18]. 
The World Health Organization (WHO) recognises three categories of epithelial tumours of 
the cervix: squamous, glandular (adenocarcinoma) and other epithelial tumours including 
adenosquamous carcinoma, neuroendocrine tumours and undifferentiated carcinoma. 
Squamous cell carcinomas account for 70%–80% of cervical cancers and 
adenocarcinomas for 20%–25%. 
  
Figure 3 - From HPV infection to cancer: developmental stages of cervical cancer, in which the mild dysplasia regresses 
spontaneously within less than a year. A proportion of the high-risk HPV (adaptaded 11) 
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2.5. Diagnosis, staging and prognostic factors 
 
Cervical tumours are staged using the Féderation Internationale de Gynécologie et 
d’Obstétrique (FIGO) classifications (Table 1). Cervical cancer is the only gynaecological 
cancer that is clinically staged based on tumour size, vaginal or parametrial involvement, 
bladder/rectum extension and distant metastases [19]. This staging system is based on 
physical examination and inspection with limited radiographic evaluation. However nodal 
status is not included, although is an important determinant in the choice of therapy and 
prognostic factor [20].    
 I. INTRODUCTION 
 
9 
Table 1- The staging of cervical tumours is by the Féderation Internationale de Gynécologie et d’Obstétrique 
(FIGO) (adaptaded 13) 
FIGO stages Definition 
I Tumour confined to the cérvix* 
IA Invasive carcinoma diagnosed only by microscopy. Stromal invasion 
with a maximal depth of 5.0mm measured from the base of the 
epithelium and a horizontal spread of 7.0mm or less** 
IA1 Measured stromal invasion 3.0mm or less in depth and 7.0mm or 
less in horizontal spread 
IA2 Measured stromal invasion more than 3.0mm and not more than 
5.0mm with a horizontal spread of 7.0mm or less** 
IB Clinically visible lesion confined to the cervix or microscopic lesion 
greater than T1a/IA2 
IB1 Clinically visible lesion 4.0 cm or less in greatest dimension 
IB2 Clinically visible lesion more than 4.0 cm in greatest dimension 
II Tumour invades beyond uterus but not to pelvic wall or to lower third 
of vagina 
IIA Tumour without parametrial invasion 
IIA1 Clinically visible lesion 4.0 cm or less in greatest dimension 
IIA2 Clinically visible lesion more than 4.0 cm in greatest dimension 
IIB Tumour with parametrial invasion 
III Tumour involves lower third of vagina, or extends to pelvic wall, or 
causes hydronephrosis or non-functioning kidney 
IIIA Tumour involves lower third of vagina 
IIIB Tumour extends to pelvic wall, or causes hydronephrosis or non-
functioning kidney 
IVA Tumour invades mucosa of the bladder or rectum, or extends 
beyond true pélvis*** 
*Extension to corpus uteri should be disregarded. 
** Vascular space involvement, venous or lymphatic, does not affect classification. 
***Bullous oedema is not sufficient to classify a tumour as T4. 
 
Laparotomy, resection of the ovarian mass and hysterectomy are main surgical techniques 
used for this staging. As well as biopsy of all suspected sites of involvement [21]. Since 
lymph node metastasis is one of the most importante prognostic factors in patients with 
early stage cervical cancer, imaging studies also should be done as appropriate [17, 18]. 
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Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI) studies are 
frequently performed for detection of metastasis in the paraaortic and pelvic lymph nodes, 
although it is impossible to differentiate metastatic nodes from nonmetastatic hyperplastic 
nodes of similar size [22]. Furthermore, MRI can determine tumour size, degree of stromal 
penetrations, parametrial involvement, vaginal extension and corpus extension with high 
accuracy (19). More recently, it has been shown that positron emission tomography (PET) 
employing the [18F] -flouro-2-deoxy-D-glucose (FDG) analogue, although more limited in 
anatomical and spatial resolution, is more sensitive than CT or MRI for detection of lymph 
node metastases in patients with cervical cancer [23]. 
Since cervical cancer remains a significant worldwide health challenge and many women 
die from the disease, it is importante to know de prognostic factors to indicate the best 
treatment [24]. The most important are lymph node status and number of lymph nodes 
involved. Tumour size, stage, depth of tumour invasion, lymphovascular space invasion 
(LVSI) and histological subtype, are other essential factors to take into account [19]. 
Although the prognostic impact of cervical cancer histology remain inconclusive, some 
authors have shown that patients with adenocarcinoma have a poorer prognosis than 
squamous cell carcinoma (SCC) histology [25, 26]. 
Papanicolaou smear and colposcopy are the main strategies for detecting cervical cancer, 
but most cases are diagnosed in late stages, especially in developing countries, and are 
therefore considered a public health problema in this regions [27].  
 
 
2.6. Treatment and side effects 
 
The treatment decision should be made based on tumor characteristics (size, stage, 
histology, lymph node (LN) involvement), possible therapeutic complications, requirement 
for adjuvant therapy and patient choice [28]. 
Surgery is the mainstay treatment option for early stages of cervical cancer [26, 27]. In the 
case of microinvasives lesions (FIGO stage IA1 and IA2) that has a low risk of spread 
beyond the cervix, are usually cured by non-radical operations such as a cone biopsy, 
trachelectomy (excision of the cervix) or simple hysterectomy [29]. However, some early 
invasive cancers (stages IA2, IB1 and some small stage IIA tumors) can also be treated 
with radiotherapy [28]. 
Standard treatment for locally advanced diseases (stage IIB to IVA) is cisplatin-based 
concurrent chemoradiation (CCRT) [30, 31]. Cisplatin works synergistically with radiation 
therapy by preventing the repair of potentially lethal damage induced by radiation, 
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enhancing sublethal damage, and potentially addressing micrometastatic distant disease 
[32]. The addition of chemotherapy to radiotherapy (RT) has proved to be more efficient 
than RT alone in terms of survival benefit, representing a major step forward in optimizing 
therapy of locally advanced cervical cancer [26, 31]. The standard administration is weekly 
cisplatin 40mg/m2 delivered in six weekly treatments, with the last cycle usually coinciding 
with the final brachytherapy [26, 30]. 
Although there are many significant advances in combined chemoradiotherapy, distance 
recurrence continues to be a major cause of treatment failure in patients with invasive 
cervical cancer. Therefore, a use of new imaging modalities, such as PET-CT, may be 
importante to guide the choice of therapy [33].  
Managing the acute and late toxic effects of treatment is one of the major challenges in 
cervical cancer therapy [30]. Hematologic toxicity is the most common acute toxicity and 
include leukopenia, anemia, neutropenia and thrombocytopenia [26, 30, 34]. These effects 
may limit the number of cycles of chemotherapy received, electrolyte abnormalities, and 
enteritis [30]. Others possibles acute effects are diarrhea, kidney toxicity and 
gastrointestinal toxicity [30, 34]. Regarding late complications, gastrointestinal toxicities and 
genotourinary can affect the quality of life of patients [26, 30].  
Radiotherapy also has an effect on healthy cells, and as a consequence there are acute 
and late side effects that change among patients. Small bowel dysfunction including 
diarrhea, abdominal cramps, dehydration, electrolyte imbalance and weight loss are some 
of the early effects of radiotherapy, while vascular changes, fibrosis, stenosis, perforation 
and necrosis characterize the late effects [35]. 
 
2.7. Outcome to treatment 
 
As mentioned, surgery, radiotherapy, chemotherapy and sometimes combination of various 
therapies are the main therapeutic strategies for cervical cancer. Although these therapies 
reduce disease symptoms, resistance of cancer cells to chemotherapy agentes and 
radiotherapy results in the recurrence of tumors [27, 33]. 
Mechanisms of cellular resistance may include decreased cytotoxic drug accumulation in 
tumour cells, alterations of detoxification mechanisms, changes in DNA repair enzymes, 
genomic alterations and regrowth potential [36].  
Although resistance of cancer cells to treatment is a primary cause of treatment failure, the 
causes are frequently multifactorial. Some of these causes may be related with unknown 
and failure to implement optimal tratment, patient factors, such as multiple pathology or 
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psychosocial factors. Furthermore, problems of normal tissue tolerance and treatment dose 
distribution, kinetic factors such as the presence of tumour cells in relatively insensitive 
phases of the cell cycle and cellular heterogeneity within tumours should also be considered 
[36]. 
Response to radiation treatment is known to depend on the well described five R's of 
radiobiology: damage repair, redistribution in cellular cycle, reoxygenation of cells, cellular 
repopulation and individual cell radiosensitivity [36]. Moreover, the efficacy of radiotherapy 
is influenced by physical and biological factors. In relation to biological factors, the most 
important are the patient’s intrinsic rate of cell proliferation and the extent of hypoxia in the 
cancer cells. Physical factors include cell kinetics, namely, the rate of proliferation in cancer 
cells correlates positively with its radiosensitivity and death by irradiation [37]. 
The efficacy of chemotherapeutics does not only depend on their ability to induce DNA 
damage, it also depends on the cell's ability to detect and respond to such damage, and the 
signaling pathways that regulate apoptosis also have a significant impact on the decision of 
the cellular response to cisplatin [38].  
 
3. DNA repair and cancer 
 
It is estimated that the human genome is constantly exposed to various damaging events 
per day [39]. The maintenance of genome integrity is important to prevent development of 
diseases associated with genomic instability including cancer, development genetic 
defects, infertility, immune deficiency and neurodegenerative disorders [40]. To protect 
genome integrity after DNA damage, cells active the DNA damage response (DDR), which 
halts cell cycle progression and facilitates repair of DNA lesions [36, 41]. 
DDR is a complex signal transduction pathway consisting of a set of strictly regulated steps, 
the initial detection of DNA damage, the recruitment of DNA repair factors to the site of the 
lesion and the final repair of the lesions. All components of signaling pathways are 
functionally categorized into harm sensors, signal transducers and effectors, which are 
hierarchically organized and communicate with each other [40].  
The sensors consist of a group of proteins, that include ataxia telangiectasia mutated (ATM) 
and ATM-and Rad3-related (ATR) and actively survey the genome for the presence of 
damage. These proteins signal the damage to three major effector pathways that together 
determine the result for the cell: checkpoints, DNA repair, and cell death [42, 43]. The whole 
DDR process is tightly controlled by post-translational modifications (PTM), including 
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phosphorylation, ubiquitination, sumoylation, methylation, acetylation and others, that been 
shown to play a pivotal role in this process (Figure 4). 
However, it is important to know the DDR defects that are present in a tumor for the 
selection of optimal treatments because the tumor cells proficient in DDR correct DNA 
damage induced by the therapy and are more resistant [38, 39]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1. Types of damage 
 
Cells are constantly exposed to DNA damaging factors including replication stress, telomere 
shortening, and a variety of exogenous and endogenous genotoxic insults [44]. Exogenous 
DNA damages include ultraviolt (UV) light, ionizing radiation (IR) and chronic environmental 
exposures (eg, cigarettes, asbestos) [40, 41]. However, the vast majority of alterations in 
DNA are certainly of endogenous origin [45]. This damages comprises numerous 
chemotherapeutic agents, as well as by-products of normal cell metabolism, namely 
reactive oxygen species (ROS) [40]. 
Ionizing radiation induces a variety of DNA lesions, being the most common to double-
strand breaks (DSB) [35, 42]. Furthermore, DNA may also indirectly to be damaged by 
ionizing radiation through the production of ROS [39]. In addition to causing DNA damage, 
irradiation initiates a signal transduction cascades that maintaining cellular homeostasis and 
promoting interactions with neighboring cells [46].  
Figure 4 - DNA damage response mechanisms (41) 
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Regarding to the direct damage, radiation directly affects the DNA molecules in the target 
tissue, causing ionization of the direct DNA or holes and electrons transferred to the DNA 
of its hydration shell [23, 47]. The indirect effect of radiation on DNA molecules includes the 
formation of free radicals by energy transfer from radiation, resulting in formation of 
molecular damage caused by the interactions of these free radicals with DNA [28]. 
Among many chemotherapy drugs that are widely used for cancer treatment, cisplatin is 
one of the most applied since it has shown effective anticancer activity in a variety of tumors 
[48]. Cisplatin acts by binding to DNA, leading to DNA adducts formation and consequently 
intrastrand or interstrand cross-links which disrupt the structure of the DNA molecule, 
promoting steric changes in the helix, inhibiting DNA replication and drive cells into 
apoptosis [49].  
Regarding to chemoradiotherapy treatment, the use of cisplatin promotes an increase in the 
number of radiation-induced strand breaks. This my occur due to the conversion of single-
strand breaks (SSBs) to double strand breaks during the repair of the platinum adducts. In 
turn, this conversion or inhibition of repair mechanisms has the effect of increasing the slope 
of the radiation survival curve and provides a better response to treatment [42].  
 
3.2. DNA repair pathways 
 
To compensate of damage that occur in DNA, cells have developed multiple repair 
mechanisms specifics for each damage type [39]. Unrepaired damage can result in 
apoptosis of the cell or can lead to unregulated cell growth and, consequently, cancer 
developement. Several cellular responses may occur in presence of DNA damages. At 
cellular level, checkpoints can be activated to arrest cell cycle, transcription can be 
regulated to compensate for damage, or cell can get in apoptose. Alternatively, DNA 
damage can be repaired, allowing the cell to reproduce normal  [50].   
Different DNA repair pathways can be activated to repair different types of DNA lesions that 
can alter their conformational structure namely, base excision repair, nucleotide excision 
repair, double strand break repair via homologous recombination (HR) or non-homologous 
end joining (NHEJ) and mismatch repair (MMR) [51]. BER pathway act in precense of small 
lesions, such as oxidized or reduced bases, fragmented or non-bulky adducts, or produced 
by methylating agents, being that the only damaged base is removed by base-specific DNA 
glycosylases. In contrast, NER pathway repairs bulky lesions such as pyrimidine dimers, 
larger chemical adducts, and cross-links.  
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There are at least two DNA double-strand break repair pathways, particulary HR pathway 
through which DNA ends are resected, posteriorly the exposed 3' single-stranded tails then 
invade the double helix of the homologous and undamaged partner molecule. Finally, 
strands are extended by DNA polymerase and cross-overs yield two intact DNA molecules.  
In its turn, NHEJ repair pathway involves direct ligation of the two damaged double-strand-
break ends. Finally, MMR pathway corrects DNA replication errors (base-base or insertion-
deletion mismatched) caused by incorrect functioning of DNA polymerase (Figure 5) [50]. 
 
 
 
 
 
 
 
 
 
 
 
However, the repair of DNA damage can be prejudicial regarding treatment response of 
cancer cells. So, it is important to take advantage of specific abnormalities in the DNA 
damage response machinery that are present in cancer cells in order to effectively kill these 
cells, but not normal cells [52]. For example, changes in the structure of the DNA molecule 
caused by cisplatin lead to recognition and repair of cellular DNA damage, which can result 
in continued cell viability, resulting in drug resistance [49]. Thus, based on the principle of 
synthetic lethality inhibition of the activity of DNA damage response proteins can be used 
to enhance chemotherapy and radiotherapy efficacy, and also to selectively kill cancer cells 
showing deficiencies certain DNA repair pathway(s) [52]. 
Synthetic lethality describes the situation where a defect in one gene or protein is 
compatible with cell viability but results in cell death when combined (synthesized) with 
another gene or protein defect [53]. This new therapeutic strategy relies on the frequent 
defects in the DNA damage response observed in cancer, in which alternative DNA damage 
response pathways may be activated to allow cancer cells to survive in the presence of 
Figure 5 - DNA damage and repair mechanisms (35) 
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genotoxic stress. Because this strategy targets the cancer-specific aberrations in the DNA 
damage response, it will cause few or no toxicities on normal cells (Figure 6) [52]. 
 
 
3.2.1. Bases Excision Repair (BER) 
 
Base excision repair is one of the major DNA damage repair pathways. This pathway can 
be define as a highly coordinated pathway of consecutive enzymatic reactions which deals 
with the most ubiquitous lesions in DNA, such as oxidative base damage, alkylation, 
deamination, sites of base loss and single-strand breaks [54]. 
BER is typically initiated by removal of the damaged base by a DNA glycosylase, resulting 
in an abasic (AP) site. These AP sites are generally repaired by apurinc/apyrmidinic 
endonuclease 1 (APE1), that hydrolyzes the phosphodiester backbone immediately 5’ to 
the AP site, creating a single-strand break flanked by 3’-OH and 5’-deoxyribose phosphate 
(5’-dRP) termini  [35, 51, 52]. These primary steps in the BER pathway are common to all 
organisms. 
The synthesis/ligation step is divided into two subpathways, the short-patch (SP) or long-
patch (LP) repair. These two alternative routes are distinguished by the size of the repair 
adhesive: one nucleotide in the case of SP repair and two or more nucleotides in the case 
of LP repair [55].  
These sub-pathways require distinct proteins, the SP repair requires relatively few proteins 
(DNA glycosylase, APE1, DNA pol β or DNA ligase I or XRCC1/DNA ligase III), whereas 
the long-patch repair critically depends on flap endonuclease (FEN1) and replicative DNA 
polymerases δ or ε, both of which require proliferating cell nuclear antigen (PCNA), other 
replication accessory proteins, and DNA ligase I for optimal activity [55].  
Figure 6 - Scheme of the principle of synthetic lethality (49) 
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Specifically, the sub pathway SP repair, that represents approximately 80-90% of all BER 
activity, encompasses the filling of a single nucleotide space and the removal of the 5’-dRP 
reticulum by DNA polymerase β and successive DNA ligation terminates by DNA ligase I or 
the DNA ligase III complex and XRCC1 protein [39]. 
The DNA repair by LP-BER subpathway happens in case the AP sites are oxidized or 
reduced, involving DNA Polδ and Polε. Once the resulting oxidized 5′-dRP cannot be 
removed by Polβ or by AP lyase-associated DNA glycosylases, FEN1 remove the dRP-
containing 5′-termini, leaving gaps spanning several nucleotides. DNA synthesis from these 
gapped DNA structures was shown to be specifically carried out by Polδ with PCNA as an 
essential elongation cofactor. Finally, DNA Lig I seals the nicked DNA to complete this BER 
sub-pathway [56]. 
XRCC1 plays a crucial role in the coordination of BER's because of its multiple interactions 
with various repair proteins. Although not catalytically active, XRCC1 is a protein capable 
of stabilizing and modifying the activity of other proteins. Besides DNA ligase IIIα, XRCC1 
interacts with several enzymes involved in the two BER subpathways including APE1 , 
polymerase beta (Pol β), polynucleotide kinase (PNK), PCNA and poly(ADP-ribose) 
polymerases 1 and 2 (PARP1/2) [57]. 
 
3.2.1.1. XRCC1 gene 
 
XRCC1 gene is a typical DNA repair gene. It is located on chromosome 19 (19q13.2) and 
consists of 17 exons encoding a 633 amino acid scaffolding protein involved in BER 
pathway (Figure 7) [58, 59].  
 
The human XRCC1 gene was identified by complementation of Chinese hamster ovary 
(CHO) cells that displayed increased sensitivity to X-rays and other DNA damaging agents, 
particularly those that generate SSBs and base lesions [60]. These cells specifically 
displayed reduced single-stranded break repair (SSBR) capacity and an increased 
frequency of sister chromatid exchange. Recently, XRCC1 deficient cells were found to 
have reduced initial repair of uracil in DNA as well. Notably, inefficient XRCC1 associated 
SSBR is reported to contribute to neurodegenerative disease in humans. 
Figure 7 - Localization of the XRCC1 gene on chromosome 19 (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=XRCC1) 
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PARPs and XRCC1 proteins are not directly involved in DNA processing, they establish 
interactions with other BER enzymes for coordinated and efficient reactions. PARP1 
possesses an enzymatic activity that polymerizes ADP–ribosyl groups onto many cellular 
factors including itself. In turn, this recruit XRCC1 which possesses the PAR-binding motif 
in its central domain and thus interacts with PAR-modified PARP1. Then, PARP1 is 
dissociated from SSBs because auto-modification results in its decreased affinity for SSBs. 
XRCC1 then coordinates the BER-repair reactions by interacting with PNKP, Polβ, and 
LigIIIα, being that the interaction with the last is essential for efficient SSBR. There are other 
BER proteins that reportedly XRCC1 interacts with to facilitate the whole BER pathway. 
These include PCNA, APE1, UNG, NEIL1, OGG1, MPG, NTL1, and NEIL2. However, 
XRCC1 is recruited on SSBs after PARP activation. Although XRCC1 was shown to 
possess intrinsic affinity for DNA, SSBs are required for efficient interaction of XRCC1 with 
DNA [56]. 
However, XRCC1 participation in DNA repair is not limited to BER/SSBR, XRCC1 
interacting factors have been shown to be involved in NHEJ and to be recruited to UVC 
induced DNA damage during NER [58]. 
It were identified nine polymorphisms in XRCC1 gene, including three commons 
substitutions: Arg194Trp, Arg280His, and Arg399Gln [61]. Studies have demonstrated that 
functional single nucleotide polymorphisms (SNPs) of XRCC1 gene are associated with 
cancer risks, such as lung cancer, bladder cancer, gastric cancer and other cancers. 
Furthermore, recente studies suggested that XRCC1 gene polymorphisms may have a 
potential role in predicting response to platinum-based chemotherapy in cervical cancer 
patients [62].  
 
3.2.2. Nucleotide Excision Repair (NER) 
 
Nucleotide Excision Repair is a highly versatile repair pathway that can recognize and 
remove a wide variety of bulky, helix-distorting lesions from DNA. The most common lesions 
are bulky covalent adducts, which are formed by nitrogenous bases affected by UV light, 
ionizing irradiation, electrophilic chemical mutagens, some drugs, and chemically active 
endogenous metabolites, including reactive oxygen and nitrogen species [63]. 
This pathway is more complex than BER pathway, requiring the coordinated action of 
approximately 30 proteins to carry out a multi-step ‘cut-and-patch’-like excision mechanism 
[35, 63]. These steps envolve recognition ofthe lesion carried out basically by the XPC-
hHR23B complex; opening of the double helix at the lesion site by the concerted action of 
the two DNA helicases XPB and XPD; demarcation of the lesion necessitating the activity 
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of the XPA and RPA proteins; dual incision of the damaged strand by the XPF and XPG 
endonucleases; synthesis of DNA in the gap left by the removal of a 24mer–32mer 
oligonucleotide by the replicative DNA polymerases and PCNA and finally ligation to the 
parental strand by DNA ligase I [64]. 
There are two damage recognition and repair sub-pathways of the NER pathway, global 
genome repair (GGR) and transcription coupled repair (TCR). TCR refers to the preferential 
repair of transcribed strands in active genes and is is activated by arresting of RNA 
polymerase II activity at the damaged sites. GGR refers to repair throughout the genome, 
including that in the non-transcribed strands of active genes and  is controlled by XPC, a 
specialized protein factor that detect the DNA damage [63, 65]. Following damage 
recognition, both sub-pathways proceed through the common ‘core’ NER reactions (42). 
Initially, either the XPC complex in GG-NER or, CSB and CSA in TC-NER recruit the multi-
subunit (ten protein complex) and the multi-functional transcription factor TFIIH to the site 
of damage. Next, two TFIIH-associated, ATP-dependent helicases XPB and XPD allow the 
asymmetric unwinding of the DNA helix to form a ∼30 nucleotide bubble flanking the lesion: 
while the XPB protein unwinds the DNA in the 3′ → 5′ direction, the XPD unwinds in the 
opposite direction [66]. This process permits access of XPA to the damaged region, which 
provides a second level of damage recognition in addition to ensuring that undamaged DNA 
is not subjected to excision repair. In the next step, two structure-specific endonucleases 
XPG and XPF/ERCC1 cleave the DNA at positions 3’ and 5’ to the damage, respectively, 
leading to excision of the lesion-containing oligonucleotide of about 30 nucleotides. The 
NER process is completed by DNA polymerase δ or ε that uses the undamaged strand as 
a template to resynthesize the resulting gap and lastly, the repaired strand is then sealed 
by DNA ligase [35, 65, 67]. 
 
3.2.2.1. ERCC2 gene 
 
The excision repair cross-complementing rodent repair deficiency group 2 (ERCC2) gene, 
also called the xeroderma pigmentosum group D (XPD) gene, is located at chromosome 
19q13.3 and comprises 23 exons. The ERCC2 gene product is a helicase protein of 760 
amino acids which belong of the transcription factor IIH (Figure 8) [64]. 
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Figure 8 - Localization of the ERCC2 gene on chromosome 19 (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=ERCC2) 
 
ERCC2 protein is a component of the general transcription factor TFIIH complex that plays 
a key role in nucleotide excision repair (NER) and basal transcription. This protein have a 
5’-3’ helicase activity and furthermore, plays a bridging function within the TFIIH complex 
[68]. 
Point mutations in the human ERCC2 protein play a causative role in DNA repair-deficiency 
diseases (xeroderma pigmentosum, trichothiodystrophy, and Cockayne syndrome), which 
are characterized by high ultraviolet-light hypersensitivity, a high mutation frequency, and 
cancer-proneness, as well as some mental and growth retardation and probably aging [64]. 
 
4. Genetic variability and influence in clinical outcome of cancer 
patients 
 
4.1. Contribution of genetic polymorphisms 
 
Genetic heterogeneity related with neoplasias is important to understand the dynamics of 
cancer progression and therapeutic resistance [69]. Changes in DNA repair genes can 
generate genomic instability and contribute to decreased repair capacity, thereby increasing 
the risk of developing cancer. Thus, it becomes important to study the role of polymorphisms 
in repair genes in cancer susceptibility and as predictors of response to therapies. Per 
definition, polymorphisms are heritable variations in the human genome that typically occur 
in 1% or greater frequency in the population being studied [70-72]. The polymorphisms can 
be Restriction Fragment Length Polymorphisms (RFLP's), Variable Number of Tandem 
Repeats (VNTR's) or Single Nucleotide Polymorphisms (SNP's) [73]. Among all kinds of 
polimorphisms, SNPs are the most abundant, accounting for 90% of known nucleotide 
variations and consist a base pair (bp) variations at specific locations in the genome. These 
single nucleotide changes are scattered throughout the genome of all species and forms 
the basis of human diversity [70, 72-74]. The number of SNPs is estimated to be 19 milion 
and occur in humans every 300-2000 base pairs (bp) along the genome [69, 70]. SNPs can 
occur in any region of the genome and depending on where a SNP occurs, it might have 
different consequences at the phenotypic level (Figure 9). SNPs can occur in noncoding 
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regions of the genome as well as in genes (introns and exons). SNPs in exonic regions can 
be of two types: non-synonymous – leading to an amino acid change and affecting the 
protein – or silent polymorphisms – not leading to an amino acid change and not affecting 
the protein. SNPs in intronic regions can produce changes in the protein sequence if they 
are located in a splicing site and can alter gene expression if they are located in a region 
encoding microRNAs. SNPs in promoter regions can increase, decrease or have no effect 
in gene expression [74, 75]. 
 
 
Due to inter-individual differences in DNA damage repair processes, the role of 
polymorphisms associated with DNA repair genes has been of increasing interest, because 
they appear to alter the functional properties of DNA repair enzymes and consequently 
influence the therapeutic response and clinical evolution of cancer patients [50, 76]. It is 
essential that there is a better understanding regarding the polymorphic variations in the 
genes and their relationship to disease condition or drug response to be helpful in optimizing 
personalized therapy and decrease the adverse effects [77].  
  
Figure 9 - The location of SNPs and their biological effects (74) 
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4.1.1. Genetic polymorphism rs1799782 in the XRCC1 gene 
 
More than 300 validated SNPs have been identified and described in the XRCC1 gene, 
however only three functional SNPs have been extensively studied being that all of which 
cause amino acid substitutions in the encoded protein [55, 57] [60, 78-81]. One of this three 
functional polymorphisms in exon 6, consist in the substitution of Cytosine (C) for an Timine 
(T) at position 26304 of codon 194, which corresponds to an amino acid exchange from a 
Arginine (Arg) to a Tryptophan (Trp) [81]. As a consequence, substitution of tryptophan with 
arginine could alter interactions between XRCC1 gene and  POLβ and PARP-1 proteins 
because the region of exon 6, in which locates Arg194Trp polymorphism encodes a highly 
conserved hydrophobic linker region between the binding domains of these two proteins 
[59]. In Europe, the frequency of the C allele is 94,8% and the T allele 5,2%. As for genotype 
frequencies, these are 90,7%, 1% and 8,3% for genotype CC, TT and CT respectively [82]. 
The presence of genetic polymorphisms in the XRCC1 gene have been shown to be 
associated with cancer susceptibility, including head and neck, esophageal, gastric, breast, 
lung, colon, cervical cancer and others [59, 76, 80]. Specifically, in relation to the XRCC1 
rs1799782 polymorphism, several studies have been developed to evaluate the risk of 
carcinogenesis for different types of cancer, including cervical cancer, however the results 
have been quite inconclusive. Until now, only two tudies evaluate the influence of this 
polymorphism in the clinical outcome cercical patients [79, 83]. Kim et al. showed that the 
genotypes of XRCC1 rs1799782 was associated with the therapeutic response [83]. 
However, another one study did not find any significant association. The inconsistent results 
may be related with the different ethnic populations and patients number included in studies 
[79]. 
 
4.1.2. Genetic polymorphism rs13181 in the ERCC2 gene 
 
Seventeen SNPs in the ERCC2 gene have recently been detected, of which six are located 
in exons and eleven in introns. One of six coding region polymorphisms located in exon 23 
the substitution of Adenine (A) for a Cytosine (C) at position 35931 of codon 751, which 
corresponds to an amino acid exchange from a Lysine (Lys) to a Glutamine (Gln). The 
751Gln variant completely changes the electronic configuration of the amino acid. This is a 
major change, located in the important domain of interaction between ERCC2 protein and 
its helicase activator, p44 protein, inside the TFIIH complex [62, 82]. This polymorphism 
was too associated with higher levels of chromatic aberrations and DNA adducts levels [79, 
83]. In Europe, the frequency of the A allele is 63,6% and the C allele 36,4%. As for 
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genotype frequencies, these are 41,7%, 14,5% and 43,7% for genotype AA, CC and AC 
respectively [84].  
Once they are very commons, SNPs in codon 751 is the subject of many epidemiological 
studies on cancer because may be associated with a reduced repair capacity and increased 
cancer susceptibility. Due to importance of the polymorphims in codon 751 of XRCC1 gene, 
this type genetic variations have been widely studied, namely in various epidemiological 
studies on cancer because appear to be associated  with a reduced DNA repair capacity 
and, consequently, increased cancer susceptibility [64]. However, regarding the 
susceptibility of this polymorphism to the development of uterine cervix cancer, no study 
has yet been performed. Regarding to the influence that this polymorphism may have on 
the response to treatment and prognosis in patients with cervical cancer, no studies have 
yet been performed. Therefore, it will be pertinent to conduct this study because of the role 
of this gene in the DNA repair pathway NER. 
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1. General aims 
 
To study the effect of the XRCC1 rs1799782 e ERCC2 rs13181 genetic polymorphisms in 
clinical evolution of patients with cervical cancer treated with concomitant 
chemoradiotherapy. 
 
2. Specific aims 
 
• To optimize the genotyping protocol of the XRCC1 rs1799782 and ERCC2 rs13181 
genetic polymorhisms. 
 
• To determine the allele and genotype distribution of the polymorphisms selected. 
 
• To compare the allele and genotype frequencies obtained in our study with those 
observed in other studies from different geographic areas and tumor models. 
 
• To evaluate the possible association between the genetic variants of the XRCC1 
and ERCC2 genes and therapeutic response, overall survival and disease-free 
survival in patients with cervical cancer. 
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1. Characterization of Population 
 
This hospital-based retrospective cohort study was performed including 260 adults patients 
with histological diagnosis of cervical cancer, at FIGO stages IB2-IVA, recruited between 
February/2002 to October/2009 from Portuguese Institute of Oncology of Porto. All patients 
were primarily treated with concurrent chemoradiation and therapeutic protocol consisted 
in weekly-cisplatin 40 mg/m2 during external radiotherapy. Patients who participated in this 
study were consecutively selected according to the following inclusion criteria: women with 
cytologic and histological diagnosis of cervical cancer, age greater than or equal to 18 years, 
stage Ib2-IVa and treated with concomitant QRT. We excluded patients who underwent 
surgery before concomitant chemoradiotherapy, cases of lack of informed consent and 
noncompliance with any of the inclusion criteria. 
Peripheral venous blood samples were obtained with the written informed consent of 
participants prior to their inclusion in the study, according to Helsinki Declaration principles. 
The study was approved by the ethics committee of Portuguese Institute of Oncology of 
Porto (CES.287/014). 
All data were obtained from medical records and patients’ clinical characteristics are 
described in Table 2. 
 
Table 2 - Patients’ clinical characteristics (N = 260) 
Clinical characteristic n % 
Age, years 
Median, 48.00 
Mean ± SD*, 49.00 ± 11.50 
 
260 
 
100 
Histological type 
Squamous cell carcinoma 
Adenocarcinoma 
Adenosquamous carcinoma 
Small cell carcinoma 
 
216 
32 
7 
5 
 
83.1 
12.3 
2.7 
1.9 
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Tumor stage (FIGO) 
Ib2 
IIa2 
IIb 
IIIa 
IIIb 
IVa 
 
22 
10 
163 
5 
53 
7 
 
8.5 
3.8 
62.7 
1.9 
20.4 
2.7 
Nodal invelvement 
Present 
No present 
 
14 
246 
 
5.4 
94.6 
Number of chemotherapy cycles 
Median, 6 (range 1 - 6) 
 
260 
 
100 
Total dose of radiotherapy 
Median, 80 (range 45 - 88) 
 
260 
 
100 
Follow-up time in months 
Median, 63.5 (range 3 - 115) 
 
260 
 
100 
Smoking habits 
Smoking 
No smoking 
No information 
 
35 
152 
73 
 
13.5 
58.5 
28.0 
Treatment response 
Complete 
Partial 
Stable 
Progression 
 
197 
45 
12 
6 
 
75.8 
17.3 
4.6 
2.3 
Recorrence 
Yes 
No 
 
50 
210 
 
19.2 
80.8 
*SD= Standard deviation. 
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2. Laboratory procedures 
 
2.1 . Extraction of genomic DNA 
 
For extraction of genomic DNA, about 8mL of peripheral venous blood was collected from 
all patients through a standard intravenous collection technique for tubes containing 
ethylenediamine tetraacetic acid (EDTA) for anticoagulant preservation. Genomic DNA was 
extracted using the GRS Genomic DNA Kit – BroadRange, according to the manufacturer’s 
protocol.  
This extraction type of the DNA through system of columns of centrifugation is based on the 
great affinity of connection of the DNA to the silica membrane that lines the columns of 
centrifugation. This procedure consists of three phases: adsorption, washing and elution. In 
first step, for the adsorption to take place, that is, the DNA binding to the silica particles, a 
buffer solution of high ionic charge and low pH must be used. In addition, ionic resins are 
present in the alcoholic solution in the membrane, which allows the denaturation of 
contaminating proteins. Subsequently, several washes are performed with different types 
of buffer solutions with ethanol, in order to remove proteins, polysaccharides and salts. 
Finally, DNA is eluted in an elution buffer, of low salt concentration and high pH. 
In accordance with manufacturer's instructions, 20μL proteinase K was added to 200μL 
peripheral blood and the mixture was incubated at 60°C during 5 minutes. Then 200 ml of 
buffer BR2 was added and mix by shaking vigorously, in order to obtain only the white blood 
cell fraction.  After this procedure, the sample was incubated again at 60°C for 5 minutes. 
Posteriorly, 200μL of ethanol was added to the lysate, and mix by shaking vigorously 
immediately for 10 seconds. Subsequently, genomic DNA mini spin column was placed in 
a 2.0 ml collection tube and sample mixture (including any precipitate if present) was 
transferred to the column, being posteriorly centrifuged at 14.000g-16.000g for 1 minute. 
Then biological samples were washed in the column, having been added 400μL of Wash 
Buffer 1 and centrifuged for 30 seconds. The flow-through was discarted and genomic DNA 
mini spin column was placed in a new collection tube. Added 600μl of Wash Buffer 2 and 
centrifuged at 14.000g-16.000g for 30 seconds. The flow-through was discarted and spin 
column was placed again in a new collection tube and centrifuged for another 3 minutes at 
14.000g-16.000g to dry the matrix of the column. In the elution phase, it was necessary 
transfer the spin column to a new 1,5-ml microcentrifuge tube and pipet 100μl preheated 
Elution Buffer directly to the centre of the spin column without touching the membrane. After 
that, the samples were incubated at room temperature for 3-5 minutes. Finally, the samples 
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were centrifuged for 30 seconds at 14.000g-16.000g to elute purified genomic DNA and 
stored at -20ºC (Figure 10).  
 
 
 
 
 
2.2 . Genotyping of XRCC1 rs1799782 and ERCC2 rs13181 polimorphysms 
 
The XRCC1 rs1799782 and ERCC2 rs13181 polymorphisms were selected according to 
the following criteria: presence of scientific evidence from previous studies in literature; 
existence of public databases that provided information about the phenotypic risk and 
biological effect of the polymorphisms and the minor allele had a frequency of at least 10% 
to 20% in normal population. The characterization of the polymorphisms selected for this 
study was performed by allelic discrimination using TaqMan methodology (Applied 
Biosystems) through real-time polymerase chain reaction (RT-PCR) technique. 
Amplification was detected and analyzed using StepOnePlus™ Real-Time PCR System 
(Applied Biosystems) software, version 2.3 (Figure 11 and 12). 
  
 
 
 
 
Figure 10 - Scheme of protocol for DNA purification from whole blood 
Figure 11 - Example of the representation of a Real Time PCR relative to ERCC2 rs13181 polymorphism 
(Blue – AA Homozigous; Green – AC Heterozigous; Red – CC Homozigous; x – Non-amplified cases; Black – 
Negative controls) 
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The Real-Time PCR technique has revolutionized the DNA amplification process because 
it allows the detection and quantification of PCR products in real time as the target DNA is 
amplified and enables amplification monitoring, increasing its accuracy and reproducibility, 
and reducing the likelihood of contamination. Allelic discrimination is based in fluorescence 
emission, through of the use of DNA-bound oligonucleotide probes. Thus, it is necessary 
that occurs to attach of two fluorometers (VIC® and FAMTM) to the 5 'end of each of the 
allelic discrimination probes, as well as the additional attachment of a minor groove binder 
(MGB) molecule to 3' end, in order to stabilize the probes in the complementary DNA strand.  
These specific probes are normaly labeled by two fluorochromes, a Reporter at the 5' end 
and a Quencher at the 3' end, which absorbs the fluorescence emited by Reporter 
fluorochrome, while the probe is intact. Because the 3' end is blocked, these probes can 
not initiate the synthesis of new DNA strands. During PCR reaction, Taq DNA polymerase 
synthesizes a new DNA strand, but during amplification of the target sequence, the probe 
Figure 12 - Representation of fluorescence curves corresponding to each genotype of the ERCC2 rs13181 
polymorphism (A – AA genotype; B – AC genotype; C – CC genotype) 
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is cleaved and hydrolyzed by the 5'->3' exonuclease activity of Taq DNA polymerase, 
leading to release of the Reporter molecule. Thus, as a result of this reaction there is an 
increase of the fluorescence emission, which will increase exponentially, during each cycle 
of PCR reaction. The allelic discrimination occurs by selective pairing of one of the probes, 
in the case of homozygosity or both for heterozygosity, using, for this purpose, the 
complementary sequence between the forward and reverse primers. The assays used in 
this study are described in table 3, as well as the respective probes labeled with 
fluorochromes specific for each allele. 
 
Table 3- Additional information of the assays used and their specific probes 
XRCC1 – rs1799782  
Assay C__11463404_10 
VIC ® Allele A 
FAMTM Allele G 
TCACCTGGGGATGTCTTGTTGATCC[A/G]GCTGAAGAAGAGAGCCCCCGGCCTC 
  
ERCC2 – rs13181  
Assay C___3145033_10 
VIC ® Allele G 
FAMTM Allele T 
TGCTGAGCAATCTGCTCTATCCTCT[G/T]CAGCGTCTCCTCTGATTCTAGCTGC 
 
For the study of both polymorphisms, the amplification reaction, which completed a final 
reaction volume of 6μL/case, contained 2.5μL of 2x Taqman Universal Master Mix, 0.125μL 
of 40x Single Nucleotide Polymorphism Genotyping Assay, 2,375μL of water Braun® sterile 
double-distilled) and 1μL DNA (~20ng). Amplification conditions were based on the 
activation of Taq DNA polymerase at 95°C for 10 minutes, followed by 45 cycles of 92°C 
for 15 seconds for denaturation and 60°C for 1 minute for primer annealing and final 
extension. 
As a quality control in the implementation of the protocol, two negative controls were 
included in each genotyping reaction to confirm the absence of contamination, genotyping 
was performed without prior knowledge of the clinical characteristics of the patients and 
allelic discrimination results were randomly repeated in 10% of samples and analyzed by 
two independent researchers. 
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2.3 . Evaluation of treatment response 
 
Treatment response was evaluated according to the criteria of Response Evaluation Criteria 
In Solid Tumors (RECIST). The complete response (CR) indicates the disappearance of the 
disease, the partial response (PR) designates that at least 50% reduction of tumor 
extension, stable disease (SD) means that the lesion presents progression less than or 
equal to 25% or a decrease less than 50%, and progression of disease (PD) indicates a 
lesion enlargement greater than 25%, or the appearance of a new lesion. In this study, 
patients with CR were included in the group of good response to therapy and patients with 
PR, SD and PD classified as having poor response. 
 
2.4 . Statistical analysis 
 
Statistical analysis was performed using SPSS software, version 22.0. The Hardy-Weinberg 
equilibrium (HWE) was calculated using the goodness-of-fit Pearson test to compare the 
genotype frequencies observed versus those expected. Analysis by Pearson chi-square 
(X2) test was used to compare the different categorical variables, with a significance level 
of 5%. A p value <0.05 was considered statistically significant. 
Overall survival was calculated from the date of diagnosis to the patient's date of death. 
Dissease free-survival was calculated in patients who achieved complete response to 
primary treatment, from the date of the end of primary treatment to the date of recurrence, 
death or last contact (which happened first). Kaplan-Meier method and Log-Rank test were 
used to obtain and analyze the survival curves.  
The relative risk calculation (HR, hazard ratio) of death were estimated by multivariate 
analysis using Cox regression method. Cox regression model was used to adjust for 
potential confounders, such as nodal involvement, ERCC2 rs13181 genotypes fitted as 
indicator variables.  
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1. Distribution of genotype and allele frequencies of 
polymorphisms XRCC1 rs1799782 and ERCC2 rs13181 
 
In 260 patients studied, regarding the XRCC1 rs1799782 polymorphism, genotype 
frequencies were 87.3%, 12.3% and 0.4% for CC, CT and TT genotypes, respectively. 
Allele frequencies were 93.5% and 6.5% for the C and T alleles, respectively. As for the 
ERCC2 rs13181 polymorphism, 46.9% of the patients are AA genotype, 43.8% AC 
genotype and 9.2% CC genotype. In this polymorphism, allele frequencies were 68.8% and 
31.2%, for the A and C alleles, respectively. The analysis of the Hardy-Weinberg Equilibrium 
in the study population, according to the genotype frequencies, showed that there are no 
statistically significant differences between observed and expected frequencies in both 
polymorphisms (p=0.910 and p=0.721 for XRCC1 and ERCC2 polymorphisms, 
respectively; Table 4). 
 Table 4- Genotype and allele frequencies of XRCC1 rs1799782 and ERCC2 rs13181 polymorphisms in cervical 
cancer patients  
Polymorphism Frequencies HWE 
 n % p 
XRCC1  
Genotype  
   CC (ArgArg) 
   CT (ArgTrp) 
   TT (TrpTrp) 
Allele  
   C (Arg) 
   T (Trp) 
Total 
 
 
227 
32 
1 
 
 
 
260 
 
 
87.3 
12.3 
0.4 
 
93.5 
6.5 
100 
 
 
 
0.910 
ERCC2 
Genotype 
   AA (LysLys) 
   AC (LysGlu) 
   CC (GlnGlu) 
Allele 
   A (Glu) 
   C (Lys) 
Total 
 
 
122 
114 
24 
 
 
 
260 
 
 
46.9 
43.8 
9.2 
 
68.8 
31.2 
              100 
 
 
 
0.721 
HWE – Hardy-Weinberg equilibrium 
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2. Comparison between allele and genotype frequencies 
obtained in this study and those observed in other studies of 
different geographical areas and tumor models 
 
Table 5 shows the allele and genotype frequencies for XRCC1 rs1799782 and ERCC2 
rs13181 polymorphisms in portuguese population analyzed in this study and in other 
populations from different geographic areas.  
Table 5- Allele and genotype frequencies for the XRCC1 rs1799782 and ERCC2 rs13181 polymorphisms in the 
portuguese population studied and in other populations from different geographic areas 
 Population N C% T% CC, n (%) CT, n (%) TT, n (%) P Ref. 
 
XRCC1 
Portuguese 
European 
Asian (China) 
Asian (China) 
Asian (Thailand) 
260 
487 
403 
322 
118 
93.5 
94 
71.6 
76.4 
76.7 
6.5 
6 
28.4 
23.6 
23.3 
227 (87.3) 
429 (88) 
202 (50) 
204 (63.4) 
65 (55.1) 
32 (12.3) 
58 (12) 
173 (43) 
84 (26.1) 
51 (43.2) 
1 (0.4) 
0 
28 (7) 
34 (10.5) 
2 (1.7) 
 
0.385 
<0.001 
<0.001 
<0.001 
 
[85]  
[86] 
[87] 
[88] 
 Population N A% C% AA, n (%) AC, n (%) CC, n (%) P Ref. 
 
ERCC2 
Portuguese 
European 
 
African 
Asian 
260 
482 
162 
156 
240 
68.8 
66 
62.7 
75 
91.7 
31.2 
34 
37.3 
25 
8.3 
122 (46.9) 
207 (43) 
69 (38.4) 
91 (58.3) 
201 (83.8) 
114 (43.8) 
227 (47) 
65 (44.3) 
52 (33.3) 
38 (15.8) 
24 (9.2) 
48 (10) 
28 (17.3) 
13 (18.3) 
1 (0.4) 
 
0.582 
0.050 
0.072 
<0.001 
 
[85] 
[89] 
[90] 
[91] 
 
By analyzing the results obtained in relation to XRCC1 rs1799782 polymoprhism, we 
observed that genotypic distribution in our study was not significantly different from other 
European population. However, it is possible to verify that there is a significantly 
difference of the genotypic distribuition between our popupation and Asian population.  
For ERCC2 rs13181 polymorphism, no significantly differences were found in genotype 
frequencies between our population and European and African populations. However, 
a statistically significant difference was observed in the distribution of ERCC2 genotypes 
between our population and Asian population.  
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Table 6 shows allele and genotype frequencies for XRCC1 rs1799782 and ERCC2 
rs13181 polymorphisms observed in other studies involving differents tumor models.  
Tabela 6- Allele and genotype frequencies for XRCC1 rs1799782 and ERCC2 rs13181 polymorphisms in the 
portuguese population studied and in other populations with different tumour models 
 
By analyzing the results obtained to XRCC1 rs1799782 polymorphism, it is possible to 
affirm that there is a significantly difference of the genotypic distribuition between our 
popupation and other tumor models (gastric cancer) and other populations with the 
same tumor model. This may mean that genotypic frequencies of our population with 
cervical cancer are different to those found in studies including populations with the 
same or different tumor models.  
Regarding the ERCC2 rs13181 polymorphism, significant differences were found in the 
genotype frequencies between our population and populations with gastrointestinal and 
lung cancers. However, no statistically significant difference was observed in the 
distribution of ERCC2 genotypes between our population and another population with 
lung, colorectal and oral cancers. Concerning the differences in the distribution of 
genotypes between our study and lung cancer populations, these are contradictory, 
given that exite two studies including lung cancer patients, but with different results.  
 
 
 Cancer N C% T% CC, n (%) CT, n (%) TT, n (%) P Ref. 
 
 
XRCC1 
Cervical  
Cervical  
Cervical  
Gastric  
260 
70 
66 
200 
93,5 
65.8 
68.9 
67.5 
6,5 
34.2 
31.1 
32.5 
227 (87,3) 
24 (48.6) 
34 (51.5) 
85 (42.5) 
32 (12,3) 
12 (34.3) 
23 (34.9) 
100 (50.0) 
1 (0.4) 
36 (17.1) 
9 (13.6) 
15 (7.5) 
 
<0.001 
<0.001 
<0.001 
 
[79] 
[83] 
[92] 
 Cancer N A% C% AA, n (%) AC, n (%) CC, n (%) P Ref. 
 
 
 
ERCC2 
Cervical  
Oral  
Gastrointestinal  
NSCLC 
NSCLC 
Coloretal  
260 
174 
80 
62 
108 
71 
68.8 
68.1 
53.75 
0.66 
94.4 
58.5 
31.2 
31.9 
46.25 
0.34 
5.6 
41.5 
122 (46.9) 
79 (45.4) 
20 (25) 
27 (43.5) 
96 (88.9) 
22 (31.0) 
114 (43.8) 
79 (45,4) 
46 (57.5) 
28 (45.2) 
12 (11.1) 
39 (55.0) 
24 (9.2) 
16 (9.2) 
14 (17.5) 
7 (11.3) 
0 
10 (14.0) 
 
0.947 
0.001 
0.834 
<0.001 
0.050 
 
[93] 
[94] 
[95] 
[96] 
[97] 
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3. Influence of the polymorphisms XRCC1 rs1799782 and 
ERCC2 rs13181 in treatment response 
 
In order to evaluate the role of the polymorphisms studied in therapeutic response, 
patients who presented a complete response were considered to be a good response, 
and patients who presented a partial response, stable disease or progressive disease 
were considered to be a poor response. 
Regarding the response type to treatment, of 260 patients included, 197 presented 
complete response, 45 partial response, 12 stable disease and 6 progressive disease. 
Thus, the good response rate was 75.8% and poor response rate was 24.2%. According 
to the CC, CT and TT genotypes of the XRCC1 rs1799782 polymorphism, good 
response rate was 87.8%, 11.7% and 0.5% respectively, and the poor response rate 
was 85.7%, 14.3% and 0%, respectively. The results showed that there was no 
significant correlation between the different genotypes and the therapeutic response 
(p=0.738). As for the ERCC2 rs13181 polymorphism, the good response rate according 
to AA, AC and CC genotypes was 47.7%, 43.7% and 8.6%, respectively, and the poor 
response rate was 44.4%, 44.4% and 11.1%, respectively. For this polymorphism, also 
no significant association was observed between the genetic variants and the response 
to treatment (p=0.805) (Table 7). 
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Table 7- Association of XRCC1 rs1799782 and ERCC2 rs13181 polymorphisms with response to 
chemoradiotherapy in patients with cervical cancer 
4. Association between overall survival and XRCC1 rs1799782 
and ERCC2 rs13181 polymorphisms 
 
Evaluation of the influence of polymorphisms under study in overall survival of patients 
with cervical cancer, it was possible to observe that overall survival time was not 
statistically different according to XRCC1 rs1799782 and ERCC2 rs13181 (p=0.761, 
Figure 13A and p=0.279, Figure 13B; respectively). In addition, the recessive model for 
polymorphism of the ERCC2 gene (CC vs AA and AC) was performed, however there 
were also no statistically significant differences between genotypes and overall survival 
(p=0.122, Figure 14). For the XRCC1 gene polymorphism it was not possible to make 
the recessive model because there is only one carrier patient of the TT genotype. 
Polymorphism Treatment response 
 Good response 
(CR) 
Poor response 
(PR+SD+PD) 
 
 n % n % p 
XRCC1 
   CC 
   CT 
   TT 
Total 
 
173 
23 
1 
197 
 
87.8 
11.7 
0.5 
100 
 
54 
9 
0 
63 
 
85.7 
14.3 
0 
100 
 
 
0.738 
ERCC2 
   AA 
   AC 
   CC 
Total 
 
94 
86 
17 
197 
 
47.7 
43.7 
8.6 
100 
 
28 
28 
7 
63 
 
44.4 
44.4 
11.1 
100 
 
0.805 
 
CR, complete response; PR, partial response; SD, stable disease; PD, progression of disease 
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Additionally, considering the recessive model for ERCC2 rs13181 polymorphism, a 
statistical analysis was performed according to some clinical-pathological data, such as the 
stage, lymph node metastasis (LNM) and age. Through this analysis, it was found that there 
is a statistically significant difference in overall survival between patients with negative 
Figure 13 - Overall survival curves obtained by the Kaplan-Meier method and log rank test in cervical cancer 
patients, according to the genotypes of the XRCC1 rs1799182 polymorphism (nTT=1; nCT=32; nCC=227; 
Figure 13A) and ERCC2 rs13181 polymorphism (nCC=24; nAC=114; nAA=122; Figure 13B) 
Figure 14 - Overall survival curves obtained by the Kaplan-Meier method and log rank test in cervical 
cancer patients, according to the recessive model for ERCC2 rs13181 polymorphism (nCC=24; nAC=114; 
nAA=122) 
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lymph nodes and different genotypes. Thus, we observed that patients carrying the CC 
genotype have a higher mean overall survival than women with at least one A allele 
(p=0.044, Figure 15). 
 
 
 
 
 
 
 
 
 
 
Furthermore, it was found that there also exists a statistically significant difference in overall 
survival between patients with locally advanced disease and negative lymph nodes and 
different genotypes. So, we observed that patients carrying the CC genotype have a higher 
mean overall survival time than women with at least one A allele (p=0.020, Figure 16). 
 
  
 
 
  
Figure 15 - Overall survival curves obtained by the Kaplan-Meier method and log rank test in cervical cancer 
patients with negative lymph nodes, according to the recessive model for ERCC2 rs13181 polymorphism 
(nCC=21; nAA/AC=223) 
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In this study, the results also showed that there is a statistically significant difference in 
overall survival between women with locally advanced disease and age greater than 39 
years and different genotypes. So, we observed that patients carrying the CC genotype 
have a higher mean overall survival than women with at least one A allele (p=0.009, Figure 
17). Additionally, by multivariate Cox regression model, adjusted for LNM prognostic factor 
(p=0.128), it was also possible to verify that women carriers of AA/AC genotypes present a 
risk of death of approximately 9 times higher than women with CC genotype [hazard ratio 
(HR), 8.92; 95% confidence interval (95% CI), 1.24–64.12; p=0.030; p=0.029, bootstrap 
analysis]. 
Figure 16 - Overall survival curves obtained by the Kaplan-Meier method and log rank test in cervical cancer 
patients with locally advanced disease and negative lymph nodes, according to the recessive model for 
ERCC2 rs13181 polymorphism (nCC=18; nAA/AC=194) 
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Finally, through a combined analysis of both polymorphisms we observed that there is a 
statistically significant difference in overall survival between women with positive lymph 
nodes and different genotypes. So, it was possible verified that patients carriers of at least 
one C allele or T allele for ERCC2 rs13181 and XRCC1 rs1799782 polymorphisms, 
respectively, have a lower mean overall survival than the other women (p=0.034, Figure 
18). 
 
  
Figure 17 - Overall survival curves obtained by the Kaplan-Meier method and log rank test in cervical cancer 
patients with locally advanced disease and age greater than 39 years, according to the recessive model for the 
ERCC2 rs13181 polymorphism (nCC=16; nAA/AC=170) 
Figure 18 - Overall survival curves obtained by the Kaplan-Meier method and log rank test in cervical 
cancer patients with positive lymph nodes according to a combined analysis for both polymorphisms 
(CC/CA ERCC2 or TT/CT XRCC1 vs. AA ERCC2 and CC XRCC1) 
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5. Association between disease-free survival (DFS) and XRCC1 
rs1799782 and ERCC2 rs13181 polymorphisms 
 
In analysis of the disease-free survival, the results showed that there were no 
statistically significant differences between different genotypes of the XRCC1 
rs1799782 polymorphism and this clinical outcome (p=0.816, Figure 19A). Regarding 
the ERCC2 rs13181 polymorphism there was also no significant relationship between 
different genotypes and disease-free survival (p=0.473, Figure 19B). Similarly, applying 
the recessive model for polymorphism in the ERCC2 gene (CC vs AA and AC) continue 
to exist no significant association with disease-free survival (p=0.228, Figure 20). 
 
 
 
 
 
 
  
Figure 19 - Disease-free survival curves obtained by the Kaplan-Meier method and log rank test in cervical cancer 
patients, according to genotypes of the XRCC1 rs1799182 (nTT=1; nCT=32; nCC=227) and ERCC2 rs13181 (nCC=24; 
nAC=114; nAA=122) polymorphisms 
 IV. RESULTS 
 
52 
 
 
 
 
 
  
 
 
 
 
 
Similarly, to performed in overall survival, considering the recessive model for ERCC2 
rs13181 polymorphism, a statistical analysis was realized according to some clinical-
pathological data, such as stage and age. The results showed that patients with ERCC2 
CC genotypes stage IIb or higher and age greater than 39 years present a statistically 
significant lower risk of developing relapse (p=0.040; Figure 21). 
 
 
 
 
. 
 
 
 
 
 
Figure 20 - Disease-free survival curves obtained by the Kaplan-Meier method and log rank test in cervical 
cancer patients, according to recessive model for ERCC2 rs13181 polymorphism (nCC=24; nAC=114; 
nAA=122) 
Figure 21 - Disease free survival curves obtained by the Kaplan-Meier method and log rank test in cervical 
cancer patients with a stage IIb or higher and age greater than 39 years according to the recessive model for 
the ERCC2 rs13181 polymorphism (nCC=16; nAA/AC=172) 
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Despite rapid advances of investigation in molecular and cell biology areas, cellular 
mechanisms by which neoplastic cells progress and acquire their metastatic ability it is 
still widely studied. However, currently, it is known that carcinogenesis is a dynamic and 
non-linear process that depends on a large number of factors, regulated at multiple 
spatial and temporal scales, which makes cancer a highly heterogeneous disease. In 
turn, this heterogeneity has implied the need to establish new strategies for prevention, 
diagnosis and treatment for cancer [98]. 
Understand the role of individual genetic variability in cancer drugs efficacy and safety 
is a major challenge in current clinical practice, concerning to drug development and 
implementation for this disease. Thus, Pharmacogenomics has become a promising 
science, since it studies the impact of genetic variation on cancer drug efficacy and 
toxicity in order to reduce the trial-and-error approach in choice of treatment and, 
thereby, to limit the exposure of the patients to ineffective and toxic drugs [99, 100]. In 
this sense, genetic variation has been recognized as an important determinant factor of 
individual variability of drug response, since it may  influence the dose-response curves 
and, consequently, the efficacy and toxicity drug in cancer patients [100]. Mutation 
events like insertions, deletions or chromossomal rearrangements can affect millions of 
base pairs, to leading variations in single nucleotides and results in DNA 
polymorphisms. Various types of polymorphism have been shown to responsible for 
variable and adverse cancer drug response, being that SNPs are the most promising 
for pharmacogenomic analysis [71]. When these genetic alterarions cause dysfunctions 
in genes encoding proteins involved in DNA repair pathways, can lead to increased 
genetic instability and, consequently, increased risk of cancer. In addition, can may 
confer resistance to cancer treatments and therefore can be considered as potential 
targets for oncologic therapy [51]. So, Pharmacogenomics predominantly is based on 
study of the SNPs, in order to fit individual genetic profile each patient, providing to an 
increase of safety and efficacy cancer treatment and, consequently, a longer patients 
survival and improvement of your life quality [71, 101].  
In the present study, we analyzed two genetic polymorphisms, XRCC1 rs1799782 and 
ERCC2 rs13181, which are involved in distintic DNA repair pathways, BER and NER, 
respectively. Currently, despite the results remain controversial, there are several 
studies that have been demonstrating an association between these polymorphisms 
and development risk of different cancer types, including cervical cancer [59, 76, 80]. 
Relatively to the influence of these genetic variants in treatment response and clinical 
outcome of cervical cancer patients, few studies have been performed, so the existing 
results are considered preliminary and inconclusive [79, 83]. In this context, this study 
was developed with purpose of evaluating the effect of these polymorphisms on the 
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clinical evolution of Caucasian patients with diagnosis of cervical cancer treated with 
concomitant chemoradiotherapy. Thus, the response to treatment was evaluated, as 
well as the different clinical outcomes, namely overall survival and disease-free survival 
of patients, according to their clinicopathological characteristics. 
 
1. Analysis of allele and genotype frequencies of the XRCC1 
rs1799782 and ERCC2 rs13181 polymorphisms 
 
In the present study, the allele frequencies of the XRCC1 rs1799782 polymorphism 
were 93.5% and 6.5% for C and T alleles, respectively, being identical to whose reported 
in others European populations. When Hardy-Weinberg equilibrium was performed, no 
statistically significant difference was observed between observed and expected 
genotype frequencies (p=0.910). Regarding the ERCC2 rs13181 polymorphism, the 
allele frequencies are similar to those observed in Europe, with a frequency of 
approximately 69% and 31% for A and C alleles, respectively. Concerning the 
distribution of genotypes, no statistically significant difference was verified between 
observed and expected frequencies, when applied Hardy-Weinberg equilibrium 
(p=0.721). The application of the Hardy-Weinberg equilibrium in studies that evaluate 
SNPs is very important, since that this assumption essentially states that unless there 
are counteracting forces, alleles frequencies will not change in a population and 
expected genotype frequencies each generation are determined by allele frequencies 
and are termed Hardy-Weinberg proportions (HWP) [102]. Deviation from these 
proportions can be caused by many factors, one of which is genotyping error [103].  
In this study, we performed a comparison between allele and genotype frequencies 
obtained and those observed in other studies of different geographic areas and tumor 
models. The discrepancy in results between our population and Asian populations may 
be due to innate genetic diversity among ethnicities, as well as various interactive 
environmental factors such as climate, diet, and lifestyle. Factors related to the study 
design or sample size should also be put into consideration. On the other hand, much 
of the alteration in the allelic frequencies of certain populations may be due to the 
existence of migration, as well as to the gene flow of populations. The comparison of 
genotype frequencies between different populations becomes essential to show the 
importance of conducting additional studies including these polymorphisms, in order to 
corroborate the results obtained and to stablish possible associatons between these 
genetic variants and prognosis of cancer patients of different geographic regions. 
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In the present study, the results of genotyping were repeated in 10% of the cases, in 
order to increase the reliability and reproducibility of the results found. In addition, 
negative controls were also used in all amplification reactions, to ensure the absence of 
contamination of the genotyped samples. It is also to conclude that the quality and 
reliability of the Real-Time PCR technique reduces the possibility of being considered 
genotyping errors. 
 
2. Association of the XRCC1 rs1799782 polymorphism with 
response to chemoradiotherapy, overall survival and 
disease-free survival in patients with cervical cancer 
 
It is well stablished that DNA damage repair is very important in the maintenance of 
genetic stability and protection against initiation of cancer development [79]. Genetic 
variations in genes involved in DNA repair could confer an increased tumoral 
susceptibility and can be associated to disease aggressiveness through of the alteration 
of DNA repair pathways, which can induce tumor transformation and acquisition of 
oncologic properties [85]. Currently chemoradiotherapy involving cisplatin is considered 
the standard treatment for some cancer types, including cervical cancer. Although 
cisplatin seems to be the most effective drug for treatment of cervical carcinoma, the 
cellular mechanisms dictating variable response to chemotherapy among patients are 
still unknown. The XRCC1 protein is a crucial member in BER pathway, and plays a 
pivotal role on repair DNA damage, including cisplatin-induced damage [87]. So, it was 
suggested that presence of SNPs in the XRCC1 gene may alter the functional ability of 
XRCC1 to repair damaged DNA, contibuting to variations in drug responses and, 
consequently, affect the success of treatment [79]. Regarding the risk of carcinogenesis, 
XRCC1 rs1799782 polymorphism is well studied in both cervical cancer and other tumor 
models including head and neck, esophageal, gastric, breast, lung, colon cancers [59, 
76, 80]. However, some studies have been evaluating the possible association between 
this polymorphism and chemotherapy response, but the results are inconsistente [79, 
83]. Possibles explanations for this inconsistency of the results may be related with the 
different types of cancers studied from diverse ethnic populations and sample size.  
Most studies that focus on assessing the possible influence of XRCC1 rs1799782 
polymorphism on clinical outcome of cancer patients undergoing cisplatin-based 
chemotherapy, include patients with non-small cell lung cancer (NSCLC) [87, 104, 105]. 
For example, Liu and colleagues performed a study including 322 NSCLC patients who 
received cisplatin-based chemotherapy and did not find significant association between 
XRCC1 genetic variants and response to chemotherapy [87]. The same inconclusive 
 V. DISCUSSION 
 
58 
result was observed in the study of Zhao et al., with 147 NSCLC patients that received 
platinum-based chemotherapy [105]. On the other hand, Sun et al. identified an 
association between XRCC1 genotypes and treatment response in 82 NSCLC patients. 
These authors verified that patients with CT genotype have a probability of about 2,33 
times higher to develop a better response to treatment than CC genotype carriers [106]. 
In addition, a meta-analysis comprising 1145 lung cancer patients concluded also that 
patients carrying CT or TT genotypes were more likely to respond to platinum-based 
chemotherapy compared with CC genotype patients [104]. 
Others two studies including patients with pancreatic adenocarcinomas treated with 
surgery, radiation and chemotherapy (including platinum agents), showed that patients 
with CC genotype have a longer overall survival than patients with TT genotype [97, 
107].  
In cervical cancer, only two studies addressing the association between this 
polymorphism and chemotherapy response and different clinical outcomes [79, 83]. In 
first study, Kim et al. evaluated the existence of a possible correlation between 
polymorphisms in genes associated with DNA synthesis and repair and response to 
neoadjuvant platinum-based chemotherapy (NAC) and disease-free survival in patients 
with cervical cancer. This study included 66 patients and by combined analysis of the 
genotypes (CC vs. CT + TT), the results indicated that there is a significantly association 
between different XRCC1 genotypes and response to NAC (p=0.023). Thus, patients 
with CC genotype presented poorer treatment responses than patients carrying CT and 
TT genotype, with CC genotype representative of the majority of poor responders. 
However, here was no correlation between XRCC1 genotypes and DFS [83]. In second 
study were analysed 70 patients with locally advanced cervical carcinoma and the 
results obtained were opposite of the previous study.  Cheng and colleagues did not 
find any significant association between XRCC1 rs1799782 polymorphism and NAC 
response, justifying the inconsistency of the results with different ethnic populations 
studied and sample size [79].  
In our study, in a general context the results showed that there was no statistically 
significant association between the genotypes of this polymorphism and therapeutic 
response (p=0.738), overall survival (OS) (p=0.761) and disease-free survival (DFS) 
(p=0.278). Thus, in relation to therapy response and disease-free survival is possible 
affirm that our results are consistent to those observed on studies of Cheng et al. and 
Kim et al., respectively, in which also no significant association was found between 
XRCC1 genotypes and these clinical endpoints. However, in study of the Kim et al., was 
observed a correlation between this polymophism and treatment response, being this 
result contradictory to that obtained in our study. So, given that the studies published 
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concerning the effect of XRCC1 rs1799782 polymorphism in prognosis of cervical 
cancer patients have been performed in Asian populations, will be needed additional 
studies in Caucasian populations in order to stablish more consistent conclusions. 
Moreover, there has been increasing evidence that decreased DNA repair capacity 
resulting from genetic polymorphisms of various DNA repair genes, namely XRCC1 
rs1799782, can be associated with improved survival of cancer patients treated with 
platinum-based chemotherapy. So, further studies would also be important to facilitate 
elucidation of the functional effect of this polymorphism in order to use it as a predictive 
and prognostic biomarker in cancer patients, particularly in patients with cervical cancer. 
 
3. Association of the ERCC2 rs13181 polymorphism with 
response to chemoradiotherapy, overall survival and 
disease-free survival in patients with cervical cancer 
 
Resistance to platinum compounds takes place through of alterations in several cellular 
mechanisms, such as decreased drug accumulation, drug inactivation, enhanced 
tolerance to platinum-DNA adducts, or enhanced DNA repair. The NER pathway is one 
of the major DNA repair systems in mammalian cells and is principal activated repair 
mechanism for the removal of bulky DNA adducts produced by platinum agents. The 
ERCC2 gene, also known as XPD, encodes a helicase that is a component of 
transcription factor TFIIH and an essential member of the NER pathway, being that 
genetic alterations in this protein can result in defective DNA repair phenotypes [97]. 
Several polymorphisms in this gene have been the subject of intense investigation 
aimed at identifying functional consequences at the level cancer prognosis and 
susceptibility, being that ERCC2 rs13181 polymorphism is the most studied. Regarding 
the risk of cervical carcinogenesis, the studies of Zhang et al. and Xiaohong et al. did 
not find any association between ERCC2 genotypes and development risk of this 
neoplasia [97, 108]. Moreover, other studies have shown that this polymorphism plays 
a key role in tumorigenesis of different types of cancers, such as hepatocellular [109], 
lung [110], leukemia [111], melanoma [112], and pancreatic cancers [113]. Concerning 
the association of this polymorphis mand response to treatment, few studies have been 
conducted so far. In this sense, two studies have been conducted to evaluate whether 
ERCC2 rs13181 polymorphism influence of the response to chemotherapy and survival 
in non-small lung cancer patients [96, 114]. In the study of Ryu et al., no statistically 
significant difference was found between the ERCC2 genetic variants both for response 
to therapy and overall survival [96]. In the other study, the authors found that the time 
of progression disease is significantly higher in patients with AC genotype than with AA 
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genotype patients [114]. Manoj et al. observed a significant increase in relapce-free 
survival but not in disease-specific survival in oral cancer patients with polymorphic 
genotype [93]. Park et al. conducted a study in patients with colorectal cancer and 
concluded that patients with AA genotype have a greater overall survival than patients 
with CC genotype [97].  
Despite of various studies published, the functional effect of the ERCC2 rs13181 
polymorphism has not yet been fully clarified, however it is thought that structural 
changes caused by the amino acid change may impact the interaction of ERCC2 with 
other members of the NER complex leading to differential DNA repair ability. 
Furthermore, this polymorphism may cosegregate with other DNA repair enzymes such 
as ERCC1 and XRCC1 because of their close proximity in the genome, thus being a 
marker for DNA repair capacity without influencing ERCC2 gene expression or protein 
function [115]. 
In order to contribute to the clarification of the ERCC2 rs13181 polymorphism role in 
treatment efficacy and prognosis of cervical cancer patients, the present study appears 
to be the first to evaluate these possible associations. The results obtained did not 
indicate any statistically significant association between different ERCC2 genotypes and 
therapeutic response (p=0.805), overall survival (p=0.279) and disease-free survival 
(p=0.473). Additionally, even by applying the recessive genetic model (CC vs. AA/AC), 
the results demonstrate that there is still no significant correlation for both overall 
survival (p=0.122) and dissease free-survival (p=0.228).  
Given this, based on recessive model, a statistical analysis was performed according to 
the lymph nodes, which is an important prognostic factor to help guide treatment 
decisions in cervical cancer. So, it was found that patients with negative lymph nodes 
and carrying the CC genotype have a higher mean overall survival than women with at 
least one A allele (p=0.044). Additionally, patients were stratified according to other 
prognostic factor, namely disease stage, since is considered one of the most important 
clinical outcome factors in choice of treatment options in patients with diagnosis of 
cervical cancer. Thus, the stages stratification considered was stages inferior or equal 
to IIa versus stages superior or equal to IIb, since several authors consider this division 
as the most ideal between early stages and locally advanced or advanced stages [116]. 
The results showed that patients group with advanced disease and negative lymph 
nodes and who are carrying the CC genotype have a higher mean overall survival than 
women carriers of A allele (p=0.020).  
The results obtained reinforce the importance of lymph nodes as a crucial prognostic 
factor of cervical cancer, influencing patient’s outcome and the choice of therapeutic 
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modality [117]. Despite the studied population presented advanced disease, the 
combination of negative lymph nodes and CC genotype results in higher overall survival. 
Biologically, this may be explained by the fact that the presence of C allele is apparently 
associated with decreased DNA repair capacity and, consequently, less viability of the 
tumor cells. 
Furthermore, patients were also stratified by age, since is a well stablished prognostic 
factor for cervical cancer and seem be important in therapeutic decision making. In this 
sense, our results showed that women group with advanced disease and age greater 
than 39 years and present the CC genotype have a higher overall survival than women 
with at least one A allele (p=0.009). This result remains significant when performed a 
Cox regression analysis adjusted for prognostic factor lymph nodes, in which it was 
verified that patients with AA/AC genotypes present a risk of death of approximately 9 
times higher than women with CC genotype (p=0.030). Additionally, in analysis 
corresponding to disease-free survival verified that patients with CC genotype and with 
advanced disease and age greater than 39 years present a statistically significant lower 
risk of developing relapse (p=0.040). Our results are consistent with others studies who 
suggest that younger age is an unfavorable prognostic factor, especially in more 
advanced stages [118, 119]. One possible explanation for this result is related with HPV 
virus infection, which is the main risk factor for cervical cancer development. HPV 
infection occurs as a large peak following sexual initiation which begins at 
approximately age 15-25 years and high-risk HPV types persist and progress to cancer 
within 10-15 years later. In addition, it is also at young age that women have multiple 
sexual partners, smoking cigarettes, immunocompromised hosts, a history of sexually 
transmitted diseases, and multiple high-risk HPV infections are therefore more likely to 
develop cervical cancer with aggressive characteristics. Thus, in older patients, the risk 
of developing high-risk HPV infections appears to be lower and, therefore, when the 
disease develops, it presents less aggressive tumor characteristics favoring a better 
prognosis [119]. 
Finally, a combined analysis of the two polymorphisms under study (XRCC1 rs1799782 
and ERCC2 rs13181) was performed and results obtained indicated that patients with 
positive lymph nodes and carriers of at least one C or T allele for ERCC2 and XRCC1 
polymorphisms, respectively, have a lower overall survival than the other patients 
(p=0.034). It can thus be concluded that in this case the polymorphisms biological effect 
is camouflaged by presence of positive lymph nodes since these seems to have more 
influence on the overall survival of patients with cervical cancer. That is, the presence 
of positive lymph nodes alone has a large negative effect on survival. 
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In order to understand whether ERCC2 rs13181 polymorphism influence the repair 
capacity of platinum-induced damage, Zhang et al. developed an in vitro transfected cell 
model and obserevd that the alteration ERCC2 AA to ERCC2 CC causes a prolonged 
S-phase of cell cycle, leading to CC genotype cells presented a slight higher apoptosis 
rate. Thus, these authors found delayed recovery from S-phase cell cycle checkpoints 
in cells with CC genotype at the time point of 24 h after cisplatin treatment. In fact, the 
absence of the ‘maintenance component’ during S phase, contrary to the G1 and G2 
checkpoints might be beneficial for cells by providing some delay but not permanent 
arrest with incompletely replicated genome. Long-term intra-S-phase blockade would 
limit the amount of sister chromatids and therefore reduce available DNA template for 
efficient repair [120]. Thus, by comparison of our results with Zhang et al. study we can 
hypothesize that the CC genotype is associated with a lower DNA repair capacity, 
resulting in presence of the damage levels increased. In addition, with the prolongation 
of the S-phase of the cell cycle and the late recovery of the checkpoints of this phase, 
which appears to exist in patients with CC genotype, damaged DNA is replicated, 
tagging the apoptosis activating pathways. Thus, there will be less viability of tumor cells 
with CC genotype and consequently a higher survival of these patients. Moreover, a 
negative lymph node status in patient’s carriers CC genotype, which is a good 
prognostic factor, leads to a better response to therapy and consequently an increased 
overall survival. 
Due to importance of the relationship between DNA repair and cancer therapy sucess, 
this research area is increasingly being explored. Thus, this study was conducted with 
the objective of contribute with new data regarding the influence of DNA repair genes 
polymorphisms on the clinical outcome of cancer patients, particularly in cervical cancer. 
In this sense, since the results obtained in our study are still preliminary, questions about 
the functionality of the XRCC1 rs1799782 and ERCC2 rs13181 polymorphisms should 
be addressed and their adjacent biological mechanisms need to be clarified.  Therefore, 
there is a need to conduct further studies addressing these genetic variants with the 
outcome clinical of cervical cancer patients, in order to use these polymorphisms as 
valid predictive and prognostic biomarkers in this neoplasia.  
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The role of genetic heterogeneity in neoplasias has become increasingly important in 
understanding the dynamics of cancer and resistance to therapy. Thus, the study of 
interindividual genetic variations, such as single nucleotide polymorphisms, has the 
potential to revolutionize medical practice by individualizing treatment, limiting patients' 
exposure to less effective or toxic drugs. Based on these genetic changes, the definition 
of susceptibility profiles for cancer development and predictors of patient’s prognosis 
may be a useful tool in the implementation of prevention strategies and in the choice of 
treatment for each patient, in order to reduce incidence and mortality by cancer. 
In this study, we highlighted the importance of polymorphisms in DNA repair genes as 
a potential biomarker for development and progression of cancer and as predictors of 
therapeutic response. In this context, two polymoprhisms were selected, namely 
XRCC1 rs1799782 and ERCC2 rs13181, in order to evaluate their influence in clinical 
outcome of patients with cervical cancer. 
 In a general way, the results showed that both polymorphisms analyzed do not 
influence the therapeutic response, overall survival and disease-free survival of 
patients. However, through analysis based on the recessive genetic model of ERCC2 
rs13181 polymorphism, it was found that women with CC genotype have an increased 
overall survival than carriers of A allele, taking into account some prognostic factors 
such as lymph nodes, stage and age. Moreover, it was also observed that patients with 
advanced disease, age over 39 years and with CC genotype have a lower risk of relapse 
than women with an A allele. 
To summarize, it is important to highlight that the present study is the first to evaluate 
the role of ERCC2 rs13181 polymorphisms as predictive and prognostic factor in 
patients with cervical cancer. Therefore, considering that the results obtained are still 
preliminary, it is important to carry out additional studies in cervical cancer, in order to 
validate the results and to futher clarify the putative functional effect of this 
polymorphism in clinical outcome of these patients. On the other hand, it would be 
interesting to study these polymorphisms in different ethinic populations in order to verify 
if these results can be extrapolated to worldwide population, independently of their 
ethnicity. Additionally, the evaluation of others polymorphisms in genes associated with 
DNA damage response, would be extremely important as it may help define a more 
individualized pharmacogenomic profile related with repair capacity of each patient.  
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Appendix I 
 
Abstract accepted for poster presentation in Eurogin congress, Lisbon, 2018. 
 
XRCC1 rs1799782 and ERCC2 rs13181 POLYMORPHISMS AS POTENTIAL 
PROGNOSTIC AND PREDICTIVE FACTORS IN CERVICAL CANCER 
PATIENTS 
 
Nogueira, Augusto1,2; Branco, Daniela1; Assis, Joana1,2; Pereira, Deolinda1,3; Bravo, 
Isabel4; Salgado, Lurdes5; Carvalho, Luísa5, Catarino, Raquel1 and Medeiros, Rui1,2,6,7 
 
1 Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute 
of Oncology of Porto (IPO-Porto), Porto, Portugal 
2 FMUP, Faculty of Medicine, University of Porto, Porto, Portugal 
3 Oncology Department, Portuguese Institute of Oncology, Porto, Portugal 
4 Medical Physics, Radiobiology and Radioprotection Group, IPO Porto-Research Center (CI-IPOP), 
Portuguese Institute of Oncology of Porto (IPO-Porto), Porto, Portugal 
5 Radiotherapy Department, Portuguese Institute of Oncology of Porto, Porto, Portugal 
6 CEBIMED, Faculty of Health Sciences of Fernando Pessoa University, Porto, Portugal 
7 Research Department, Portuguese League against Cancer (NRNorte), Porto, Portugal 
 
Background/Objectives: Cancer cells efficiently repair treatment-induced DNA damage, 
exhibiting greater resistance to radiation or DNA damaging agents.  Cervical cancer is 
commonly treated by platinum-based chemoradiotherapy, and the inactivation of DNA 
repair may increase the efficacy of treatments. Given that genetic polymorphisms seem to 
influence the repair capacity of tumor cells and can be identified by using blood samples, 
they are promising biomarkers in the clinical decision-making process for cancer patients. 
Thus, the aim of present study was to assess the prognostic and predictive values of 
XRCC1 rs1799782 and ERCC2 rs13181 polymorphisms in cervical cancer patients.  
Material/Methods: This retrospective hospital-based study includes a total of 260 
Caucasians patients with histologically confirmed cervical carcinoma (FIGO stage IB2-IVA). 
The patients were recruited between February 2002 and October 2009 and treated with 
cisplatin-based concomitant chemoradiotherapy in Portuguese Institute of Oncology of 
Porto. The genotyping was performed using Taqman™ Allelic Discrimination methodology 
by Real-Time PCR. Difference in frequencies of the genotype between the different therapy 
responses groups were evaluated by χ2 test.  Overall survival (OS) and disease-free survival 
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(DFS) were estimated by Kaplan-Meier method and log-rank test. A level of P<0.05 was 
considered statistically significant.  
 
Results: There were no significant statistical differences between the different genotypes 
of the XRCC1 rs1799782 and ERCC2 rs13181 polymorphisms and treatment response 
(P=0.738 and P=0.805, respectively). Concerning the OS, we observed that patients with 
advanced disease, negative lymph nodes metastasis (LNM) and carriers of ERCC2 CC 
genotypes present a higher survival when compared with carriers at least one A allele 
(AA/AC genotypes) (P=0.020). Additionally, we verified that carriers ERCC2 CA/AA 
genotypes carrier patients present a risk of death of approximately 9 times higher than 
patients with the CC genotype, adjusted for LNM prognostic factor (P=0.030; P=0.029, 
bootstrap analysis). 
The results also showed that patients group with stage IIb or higher, age above 39 years 
old and carriers of ERCC2 CC genotypes present a statistically significant lower risk of 
developing relapse than CA/AA genotypes carrier patients (P=0.040). 
 
Conclusions: In conclusion, we demonstrated the clinical significance of polymorphisms in 
DNA repair genes in cervical cancer patients. The ERCC2 rs13181 polymorphism might be 
used as a prognostic marker for patients undergoing cisplatin-based chemoradiotherapy. 
However, additional studies are required for validation these results. 
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